Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
 & Lead Plaintiff Deadline: February 14, 2017 - EconoTimes)
NEW YORK, Dec. 27, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Illumina Inc. (“Illumina” or the “Company”) (NASDAQ:ILMN) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Illumina securities between July 26, 2016 and October 10, 2016, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/ilmn.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) that Illumina was suffering a large decline in its instrument sales; (2) that this decline was damaging Illumina’s revenue; (3) that Illumina lacked visibility into trends that could have a substantial impact on its financial results; (4) that, as such, Illumina’s revenue guidance was unreliable and overstated; and (5) consequently, Illumina’s statements its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On October 10, 2016 Illumina announced its disappointing financial results for the third quarter of fiscal year 2016. Previously, the company had predicted revenues of $625 to $630 million for the quarter. Now mentioning “declining demand for its high-speed genetic sequences,” Illumina generated just $607 million. Following this news, Illumina stock dropped as much as 25% during intraday trading on October 11, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ilmn or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Illumina you have until February 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
